10 phenotype and exposure intensity in sensitization to complex platinum salts,” American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 2, pp. 435–438, 1999. [68] M. Markman, K. Zanotti, B. Kulp, G. Peterson, and M. Markman, “Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hyper- sensitivity,” Gynecologic Oncology, vol. 89, no. 3, pp. 514–516, 2003. [69] A. Gadducci, R. Tana, G. Teti, G. Zanca, A. Fanucchi, and A. R. Genazzani, “Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer,” International Journal of Gynecolog- ical Cancer, vol. 18, no. 4, pp. 615–620, 2008. [70] M. Navo, A. Kunthur, M. L. Badell et al., “Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients,” Gynecologic Oncology, vol. 103, no. 2, pp. 608–613, 2006. [71] J. R. Schwartz, C. Bandera, A. Bradley et al., “Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants’ Hospital,” Gynecologic Oncology, vol. 105, no. 1, pp. 81–83, 2007. [72] A. Bamias, K. Syrigos, G. Fountzilas et al., “Intensiﬁed bimonthly cisplatin with bolus 5-ﬂuorouracil, continuous 5- ﬂuorouracil and high-dose leucovorin (LV5FU2) in patients with advanced gastrointestinal carcinomas: a phase I dose- ﬁnding and pharmacokinetic study,” American Journal of Clinical Oncology, vol. 27, no. 5, pp. 465–471, 2004. [73] Y. Ichikawa, A. Goto, S. Hirokawa et al., “Allergic reactions to oxaliplatin in a single Institute in Japan,” Japanese Journal of Clinical Oncology, vol. 39, no. 9, pp. 616–620, 2009. [74] E. Pujade-Lauraine, U. Wagner, E. Aavall-Lundqvist et al., “Pegylated liposomal Doxorubicin and Carboplatin com- pared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse,” Journal of Clinical Oncology, vol. 28, no. 20, pp. 3323–3329, 2010. [75] M. Markman, J. Moon, S. Wilczynski et al., “Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: ﬁnal survival results of a SWOG (S0200) phase 3 randomized trial,” Gynecologic Oncology, vol. 116, no. 3, pp. 323–325, 2010. [76] G. M. Shepherd, “Hypersensitivity reactions to chemother- apeutic drugs,” Clinical Reviews in Allergy and Immunology, vol. 24, no. 3, pp. 253–262, 2003. [77] E. Syrigou, K. Syrigos, and M. W. Saif, “Hypersensitivity reactions to oxaliplatin and other antineoplastic agents,” Current Allergy and Asthma Reports, vol. 8, no. 1, pp. 56–62, 2008. [78] A. Goldberg, R. Conﬁno-Cohen, A. Fishman, Y. Beyth, and M. Altaras, “A modiﬁed, prolonged desensitization proto- col in carboplatin allergy,” Journal of Allergy and Clinical Immunology, vol. 98, no. 4, pp. 841–843, 1996. [79] E. Enrique, T. Malek, J. V. Castello´ , and J. A. de Mateo, “Use- fulness of skin testing with platinum salts to demonstrate lack of cross-reactivity between carboplatin and cisplatin,” Annals of Allergy, Asthma and Immunology, vol. 100, no. 1, p. 86, 2008. [80] O. Cromwell, J. Pepys, W. E. Parish, and E. G. Hughes, “Speciﬁc IgE antibodies to platinum salts in sensitized workers,” Clinical Allergy, vol. 9, no. 2, pp. 109–117, 1979. [81] D. Santini, G. Tonini, A. Salerno et al., “Idiosyncratic reaction after oxaliplatin infusion,” Annals of Oncology, vol. 12, no. 1, pp. 132–133, 2001. Metal-Based Drugs [82] M.-Y. Lee, M.-H. Yang, J.-H. Liu et al., “Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication,” Supportive Care in Cancer, vol. 15, no. 1, pp. 89–93, 2007. [83] C. Garuﬁ, S. Vaglio, S. Brienza et al., “Immunohemolytic anemia following oxaliplatin administration,” Annals of Oncology, vol. 11, no. 4, p. 497, 2000. [84] R. R. Thomas, M. G. Quinn, B. Schuler, and J. L. Grem, “Hypersensitivity and idiosyncratic reactions to oxaliplatin,” Cancer, vol. 97, no. 9, pp. 2301–2307, 2003. [85] R. S. de Vries, E. J. Mattijssen, and A. A. van Sorge, “Serious delayed hypersensitivity reaction to oxaliplatin,” Annals of Oncology, vol. 17, no. 11, pp. 1723–1724, 2006. [86] M. Morgan, D. C. Bowers, R. S. Gruchalla, and D. A. Khan, “Safety and eﬃcacy of repeated monthly carboplatin desensitization,” Journal of Allergy and Clinical Immunology, vol. 114, no. 4, pp. 974–975, 2004. [87] A. Vekris, D. Meynard, M.-C. Haaz, M. Bayssas, J. Bonnet, and J. Robert, “Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research,” Cancer Research, vol. 64, no. 1, pp. 356–362, 2004. [88] D. P. Greene, J. S. Ferriss, and A. A. Jazaeri, “Cisplatin administration following carboplatin desensitization fail- ure in primary peritoneal cancer: a brief report,” Cancer Chemotherapy and Pharmacology, vol. 66, no. 2, pp. 265–267, 2010. [89] D. S. Dizon, P. J. Sabbatini, C. Aghajanian, M. L. Hensley, and D. R. Spriggs, “Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy,” Gynecologic Oncology, vol. 84, no. 3, pp. 378–382, 2002. [90] S. Zweizig, L. D. Roman, and L. I. Muderspach, “Death from anaphylaxis to cisplatin: a case report,” Gynecologic Oncology, vol. 53, no. 1, pp. 121–122, 1994. [91] F. Maindrault-Goebel, T. Andre´, C. Tournigand et al., “Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients,” European Journal of Cancer, vol. 41, no. 15, pp. 2262–2267, 2005. [92] S. Potenza, G. Nasti, O. Alessandro, A. Filippelli, F. Rossi, and A. Capuano, “Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction,” Investigational New Drugs, vol. 28, no. 2, pp. 185–186, 2010. [93] M. W. Saif, S. Roy, L. Ledbetter, J. Madison, and K. Syrigos, “Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction,” World Journal of Gastroenterology, vol. 13, no. 39, pp. 5277–5281, 2007. [94] M. W. Saif, K. I. Syrigos, S. Hotchkiss et al., “Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 1, pp. 107–112, 2009. [95] J. M. Montiel Herrera, M. A. Go´ ngora-Melendez, M. L. Pineda-Maldonado et al., “Carboplatin hypersensitivity and desensitization in an infant,” Therapeutic Drug Monitoring, vol. 32, no. 4, pp. 525–528, 2010. [96] M. Markman, “Hypersensitivity reactions to carboplatin,” Gynecologic Oncology, vol. 84, no. 2, pp. 353–354, 2002. [97] A. Polyzos, N. Tsavaris, C. Kosmas et al., “Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience,” Oncology, vol. 61, no. 2, pp. 129–133, 2001.